source
- RevMed stock rises on early Rasonque sales as whistleblower sues Madrigal over MASH safetyRevMed announced its first sales figures for Rasonque, a therapy targeting pancreatic cancer, and the news sent the company's shares higher. The company said the early sales data reflect market up…
- Caldera and Evommune secure China licensing agreements for autoimmune drug assetsCaldera and Evommune announced they have entered licensing agreements with Chinese partners to bring their autoimmune drug programs to the Chinese market. The deals come as the biopharma sector is…